[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531233":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":40,"collaborators":10,"id":42,"slug":10,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Fujian Cancer Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"cervical cancer patients with radiotherapy",null,"Radiotherapy is the main treatment strategy with an overall dose of over 75Gy.",[13],"Radiation: Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .","The chemotherapy regimens included cisplatin (40 mg\u002Fm2) or nedaplatin (80 mg\u002Fm2) monotherapy or combined with paclitaxel (135 mg\u002Fm2) every three weeks during radiotherapy.",[9],[21],"concurrent chemothearpy",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Yang Sun","CONTACT","+8615959028989","sunyang@fjzlhospital.com",[29],{"facility":5,"status":10,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"Fuzhou","Fujian","350014","China",{"type":35,"coordinates":36},"Point",[37,38],119.30611,26.06139,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100531233",false,"NCT06197126","MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy","A Prognostic Model Based on MRI for Cervical Cancer Patients Treated With Radiotherapy","Inclusion Criteria:\n\n* (1) pathologically confirmed CC, (2) initially treated in our center\n\nExclusion Criteria:\n\n* (1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up","FEMALE","20 Years","85 Years",{"count":52,"type":53},200,"ESTIMATED","OBSERVATIONAL","This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.",[57,58,59,60],"Cervical Cancer","Radiotherapy","Prognostic Model","MRI","NOT_YET_RECRUITING","2023-12-25",{"date":64,"type":65},"2024-01-09","ACTUAL",{"date":67,"type":53},"2024-01-01",{"date":69,"type":53},"2028-12-31",{"name":5,"class":6},1]